MARKET

CYTK

CYTK

Cytokinetics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.65
-3.50
-8.30%
After Hours: 40.16 +1.51 +3.91% 17:22 05/18 EDT
OPEN
41.02
PREV CLOSE
42.15
HIGH
42.16
LOW
38.45
VOLUME
1.19M
TURNOVER
4.65M
52 WEEK HIGH
47.90
52 WEEK LOW
17.72
MARKET CAP
3.31B
P/E (TTM)
-12.0009
1D
5D
1M
3M
1Y
5Y
Insider Sell: Cytokinetics
MT Newswires · 11h ago
BRIEF-Cytokinetics and ALS Association Renew Partnership
reuters.com · 17h ago
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the...
GlobeNewswire · 17h ago
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 2022 H.C. Wainwright Global Life Sc...
GlobeNewswire · 1d ago
BRIEF-Cytokinetics Provides Regulatory Update Related To New Drug Application For Omecamtiv Mecarbil
reuters.com · 1d ago
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
FDA Plans to Convene Advisory Committee MeetingSOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food...
GlobeNewswire · 1d ago
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an International Congress of the European Society of Cardiology taking ...
GlobeNewswire · 2d ago
Cytokinetics rallies after Mizuho raises price target to $80
Cytokinetics (NASDAQ:CYTK) is up 5% in early trading as Mizuho raised the biotech's price target to $80 from $54 in a research note issued on Monday. The firm's revised target price implies
Seekingalpha · 2d ago
More
No Data
Learn about the latest financial forecast of CYTK. Analyze the recent business situations of Cytokinetics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

15.38%Strong Buy
84.62%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CYTK stock price target is 61.00 with a high estimate of 80.00 and a low estimate of 46.00.
High80.00
Average61.00
Low46.00
Current 38.65
EPS
Actual
Estimate
-0.84-0.63-0.42-0.21
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 316
Institutional Holdings: 94.64M
% Owned: 110.50%
Shares Outstanding: 85.65M
TypeInstitutionsShares
Increased
83
5.66M
New
50
3.15M
Decreased
78
7.11M
Sold Out
10
539.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.24%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Non-Executive Chairman/Independent Director
John Henderson
Chief Executive Officer/President/Director
Robert Blum
Chief Financial Officer/Senior Vice President
Ching Jaw
Chief Human Resource Officer/Chief Administrative Officer
David Cragg
Executive Vice President
Andrew Callos
Executive Vice President
Fady Malik
Chief Accounting Officer/Vice President
Robert Wong
Independent Director
Muna Bhanji
Independent Director
Santo Costa
Independent Director
Robert Harrington
Independent Director
Edward Kaye
Independent Director
B. Lynne Parshall
Independent Director
Sandford Smith
Independent Director
Wendell Wierenga
Independent Director
Nancy Wysenski
No Data
No Data
About CYTK
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Webull offers kinds of Cytokinetics, Inc. stock information, including NASDAQ:CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.